Literature DB >> 24634200

Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease.

Yali Cao1, Zhigang Tian, Wenge Li, Li Ma, Yongchao Yu, Wenwen Ren.   

Abstract

OBJECTIVE: The prevalence and significance of treatment resistance and relapse in patients from China with antineutrophil cytoplasmic antibody-associated (ANCA) disease are poorly understood.
METHODS: A total of 98 patients with ANCA vasculitis, diagnosed between January 2003 and December 2009 in the China-Japan Friendship Hospital, were enrolled in this retrospective study.
RESULTS: Fifteen patients (15.3%) were categorized as having cytoplasmic and/or proteinase 3 (PR3) ANCA and 83 patients (84.7%) had perinuclear and/or myeloperoxidase (MPO) ANCA. After the induction phase treatment, the disease was resistant to therapy in 24 (25%) of the patients. A response to initial treatment occurred in 74 patients (75%). Of these 74 patients, remission was achieved and sustained with or without maintenance therapy in 41 patients (55%). Multivariable logistic regression models revealed that female sex was a statistically significant predictor of treatment resistance (OR 2.85; 95% CI: 1.06-2.86; p = 0.036). Additionally, elevated serum creatinine level, with each increment of 150 μmol/l, predicted resistance (p = 0.002). Among the 74 patients where remission was achieved, Cox proportional hazards models detected that those with PR3 ANCA were 1.31 times more likely to experience a relapse than were patients with MPO ANCA (95% CI: 1.01-5.35; p = 0.0001). Lung involvement was associated with an increased risk of relapse (HR 1.87; 95% CI: 1.12-4.35; p = 0.014). Although not significant, advanced age tended to be associated with relapse (p = 0.08).
CONCLUSION: Our findings highlight the important effect of female sex and severity of renal disease at presentation as predictors of treatment resistance, and PR3 ANCA and lung involvement as predictors of relapse.

Entities:  

Keywords:  ANTINEUTROPHIL CYTOPLASMIC ANTIBODY; PROTEINASE 3; RELAPSE; REMISSION; TREATMENT RESISTANCE

Mesh:

Substances:

Year:  2014        PMID: 24634200     DOI: 10.3899/jrheum.130758

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Risk factors for treatment resistance and relapse of Chinese patients with MPO-ANCA-associated vasculitis.

Authors:  Li Huang; Chanjuan Shen; Yong Zhong; Joshua D Ooi; Ya-Ou Zhou; Jin-Biao Chen; Ting Wu; Ting Meng; Zhou Xiao; Wei Lin; Xiang Ao; Xiangcheng Xiao; Qiaoling Zhou; Ping Xiao
Journal:  Clin Exp Med       Date:  2020-02-20       Impact factor: 3.984

Review 2.  Predictors of Poor Outcome in ANCA-Associated Vasculitis (AAV).

Authors:  Luis E Vega; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2016-12       Impact factor: 4.592

Review 3.  The Prevalence and Management of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in China.

Authors:  Zhi-Ying Li; Tian-Tian Ma; Min Chen; Ming-Hui Zhao
Journal:  Kidney Dis (Basel)       Date:  2015-12-09

4.  Relevance of ANCA positivity at the time of renal transplantation in ANCA associated vasculitis.

Authors:  Duvuru Geetha; Scott M Lee; Shivani Shah; Hafizur M Rahman
Journal:  J Nephrol       Date:  2015-12-08       Impact factor: 3.902

5.  Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.

Authors:  Lynn A Fussner; Amber M Hummel; Darrell R Schroeder; Francisco Silva; Rodrigo Cartin-Ceba; Melissa R Snyder; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; Nadia K Tchao; John H Stone; Ulrich Specks
Journal:  Arthritis Rheumatol       Date:  2016-07       Impact factor: 10.995

Review 6.  Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy.

Authors:  Maurizio Salvadori; Aris Tsalouchos
Journal:  World J Nephrol       Date:  2018-05-06

7.  Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.

Authors:  Gwen E Thompson; Lynn A Fussner; Amber M Hummel; Darrell R Schroeder; Francisco Silva; Melissa R Snyder; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; John H Stone; Ulrich Specks
Journal:  Front Immunol       Date:  2020-09-03       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.